Seqirus will invest £40 million into its U.K. site, adding about 100 jobs so it can shorten production time for its Fluad influenza vaccine.
The FDA has slapped a warning letter on a Chinese company that shipped multiple lots of an OTC product to the U.S. that contained the wrong API.
A Danish medicines repackager has again had its manufacturing certificate yanked by regulators just months after it said it had resolved its problems.
India’s Lupin has received a warning letter for two of its plants in India, one which it is key to launching new drugs in the U.S.
Hours after Roche confirmed 130 workers will be cut from a California site by year-end, it said it will shave 235 jobs from an EU packaging plant.
AmerisourceBergen's costs to resolve federal litigation tied to syringe sold from an unregistered facility have more than doubled to $575 million.
Roche’s Genentech will cut 130 jobs by year-end at a California biologics plant due to biosimilar competition over top cancer drugs.
The FDA has banned the OTC products of a Canadian drugmaker after finding it was using ingredients from a supplier already on its import alert list.
Manufacturing issues at legacy Hospira plants have taken a toll on Pfizer’s earnings and created serious problems for some of its clients.
Biocon has seen its earnings hit by FDA and EU regulatory issues at its Indian plant that makes the biosimilars it and partner Mylan have developed.